2nd Quarter - Report

HEALTH CARE SERVICE CORPORATION, A MUTUAL LEGAL RESERVE COMPANY (HCSC) for HEALTH CARE SERVICE CORPORATION, A MUTUAL LEGAL RESERVE COMPANY (HCSC)

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$1,430,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
2nd Quarter - Report (this page) Jul 22, 2019 $1,430,000 Replaced
2nd Quarter - Amendment Feb 25, 2020 $1,460,000 Replaced
2nd Quarter - Amendment Dec 17, 2020 $1,710,000 Yes

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

H.R. 1781 - Payment Commission Data Act of 2019: Issues regarding providing the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to drug pricing and rebate data. H.R. 938 - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019: Issues regarding discouraging parking of 180-day exclusivity by a first generic applicant that is blocking the approval of other generics. H.R. 1520 - Purple Book Continuity Act of 2019: Issues regarding codifying publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book; Publication and regular updating of the Purple Book electronically on the FDAs website. H.R. 1503 - Orange Book Transparency Act of 2019: Issues regarding ensuring that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019: Issues regarding brand-name and generic drug manufacturers entering into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market. H.R. 965, S. 340 - Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: Issues regarding processes by which generic manufacturers can obtain sufficient quantities of brand drug samples for testing. H.R. 1385 - State Allowance for a Variety of Exchanges (SAVE) Act: Issues regarding federal funds to establish state-based Marketplaces. H.R. 1386 - Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act: Issues regarding funding for Federally-Facilitated Marketplace navigator program; requirements for navigator entities in each state; Health and Human Services ensuring that navigator grants are awarded to entities with demonstrated capacity to carry out the duties specified in the Affordable Care Act. H.R. 987 - Marketing and Outreach Restoration to Empower (MORE) Health Education Act of 2019: Issues related to restoring outreach and enrollment funding to assist consumers in signing up for health care. H.R. 1010 - Issues regarding Short-Term, Limited Duration Insurance. H.R. 986 - Protecting Americans with Preexisting Conditions Act of 2019: Issues regarding rescinding Section 1332 guidance of the ACA promulgated in October 2018. H.R. 1425 - State Health Care Premium Reduction Act: Issues regarding state reinsurance program and providing financial assistance to reduce out-of-pocket costs. H.R. 820 - Public Health Service Act: Issues regarding National Institutes of Health support to collect the medical specimens and information of children with selected cancers that have the least effective treatments. H.R. 2069 - The SPIKE Act, H.R. 2113 - STAR Act, H.R. 2115 - Public Disclosure of Drug Discounts Act, H.R. 2296 - FAIR Drug Pricing Act, H.R. 2376 - Prescription Pricing for the People Act, H.R, 2757 - Creating Lower Cost Alternatives for Your Prescription Drugs Act, S. 657 - Drug Price Transparency (DPT) Act: Issues relating to drug and price transparency. H.R. 3253 - Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act of 2019: Regarding all provisions. S. 1895 - The Lower Health Care Costs Act: Regarding all provisions. S. 80, S. 172 - Issues regarding repeal and delay of the health insurer fee. Issues pertaining to surprise billing, including benchmark payments and arbitration models.

LobbyistCovered position, as disclosed
THERESA DOYLE —
DANIEL R. JONES —
JERRY STEFFL —

Contacted: Health & Human Services, Dept of (HHS); White House Office; Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1503 (116th), H.R. 1520 (116th), H.R. 3253 (116th), H.R. 987 (116th), S. 340 (116th), H.R. 2296 (116th), S. 80 (116th), H.R. 986 (116th), H.R. 2069 (116th), H.R. 1386 (116th), H.R. 1385 (116th), H.R. 1425 (116th), S. 1895 (116th), H.R. 820 (116th), H.R. 2113 (116th), H.R. 2376 (116th), S. 172 (116th), H.R. 938 (116th), H.R. 2115 (116th), H.R. 1499 (116th), S. 657 (116th), H.R. 965 (116th), H.R. 1010 (116th), H.R. 1781 (116th)

Medicare/Medicaid MMM

H.R. 3325, S. 428 - ACE Kids Act, H.R. 7217 - IMPROVE Act: Issues pertaining to Part D rebates; 2020 Notice of Benefit and Payment Parameters, Money Follows the Person, Medicaid Medical Loss Ratio.

LobbyistCovered position, as disclosed
THERESA DOYLE —
DANIEL R. JONES —
JERRY STEFFL —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); White House Office; Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 3325 (116th), S. 428 (116th), H.R. 7217 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.